Patents Assigned to The Institute for Ethnomedicine
-
Patent number: 11974551Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).Type: GrantFiled: July 12, 2021Date of Patent: May 7, 2024Assignee: THE INSTITUTE FOR ETHNOMEDICINEInventors: Paul Alan Cox, Sandra Anne Banack, Deborah C. Mash
-
Patent number: 11917986Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).Type: GrantFiled: March 28, 2014Date of Patent: March 5, 2024Assignee: THE INSTITUTE FOR ETHNOMEDICINEInventors: Paul Alan Cox, Sandra Anne Banack, Deborah C. Mash
-
Patent number: 11700840Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).Type: GrantFiled: October 6, 2017Date of Patent: July 18, 2023Assignee: THE INSTITUTE FOR ETHNOMEDICINEInventors: Kenneth Rodgers, Rachael Dunlop, Paul A. Cox
-
Patent number: 10048278Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of ?-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.Type: GrantFiled: September 20, 2013Date of Patent: August 14, 2018Assignee: THE INSTITUTE FOR ETHNOMEDICINEInventors: Paul Alan Cox, Sandra Banack, Susan Murch
-
Publication number: 20180027781Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).Type: ApplicationFiled: October 6, 2017Publication date: February 1, 2018Applicant: THE INSTITUTE FOR ETHNOMEDICINEInventors: Kenneth Rodgers, Rachael Dunlop, Paul A. Cox
-
Patent number: 8603753Abstract: An immunoassay for screening a sample to detect the presence of ?-N-methylamino-L-alanine (BMAA) is disclosed. Antibodies specific for BMAA are disclosed. Antibodies that bind to BMAA on immunoblots are disclosed. Immunoassays and kits to detect the presence of BMAA in a sample by contacting the sample with an antibody that binds to BMAA, and detecting the antibody bound to the sample, are disclosed. Immunoassays and kits for screening for the presence of BMAA in a subject by analyzing a tissue sample obtained from the subject to detect the present of BMAA in the tissue sample, where the presence of BMAA in the tissue sample indicates exposure of the subject to an environmental source of BMAA, are disclosed. Immunoassays and kits for detecting an environmental source of BMAA, by screening an environmental sample to detect the presence of BMAA in the sample, wherein the presence of a detectable amount of BMAA in the sample indicates the sample is an environmental source of BMAA, are disclosed.Type: GrantFiled: July 2, 2009Date of Patent: December 10, 2013Assignees: The Institute for Ethnomedicine, The University of DundeeInventors: Paul Alan Cox, James S. Metcalf, Geoffrey A. Codd
-
Patent number: 8541184Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of ?-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.Type: GrantFiled: January 27, 2011Date of Patent: September 24, 2013Assignee: The Institute for EthnomedicineInventors: Paul Alan Cox, Sandra Banack, Susan Murch
-
Publication number: 20130156846Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).Type: ApplicationFiled: November 21, 2012Publication date: June 20, 2013Applicant: THE INSTITUTE FOR ETHNOMEDICINEInventor: THE INSTITUTE FOR ETHNOMEDICINE
-
Publication number: 20110223624Abstract: An immunoassay for screening a sample to detect the presence of ?-N-methylamino-L-alanine (BMAA) is disclosed. Antibodies specific for BMAA are disclosed. Antibodies that bind to BMAA on immunoblots are disclosed. Immunoassays and kits to detect the presence of BMAA in a sample by contacting the sample with an antibody that binds to BMAA, and detecting the antibody bound to the sample, are disclosed. Immunoassays and kits for screening for the presence of BMAA in a subject by analyzing a tissue sample obtained from the subject to detect the present of BMAA in the tissue sample, where the presence of BMAA in the tissue sample indicates exposure of the subject to an environmental source of BMAA, are disclosed. Immunoassays and kits for detecting an environmental source of BMAA, by screening an environmental sample to detect the presence of BMAA in the sample, wherein the presence of a detectable amount of BMAA in the sample indicates the sample is an environmental source of BMAA, are disclosed.Type: ApplicationFiled: July 2, 2009Publication date: September 15, 2011Applicant: THE INSTITUTE FOR ETHNOMEDICINEInventors: Paul Alan Cox, James S. Metcalf, Geoffrey A. Codd
-
Publication number: 20110183424Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of ?-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.Type: ApplicationFiled: January 27, 2011Publication date: July 28, 2011Applicant: THE INSTITUTE FOR ETHNOMEDICINEInventors: Paul A. Cox, Sandra A. Banack, Susan J. Murch
-
Patent number: 7901895Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of ?-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.Type: GrantFiled: August 13, 2007Date of Patent: March 8, 2011Assignee: The Institute for EthnomedicineInventors: Paul A Cox, Sandra Banack, Susan Murch
-
Patent number: 7670783Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of ?-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.Type: GrantFiled: June 8, 2007Date of Patent: March 2, 2010Assignee: The Institute for EthnomedicineInventors: Paul A Cox, Sandra Banack, Susan Murch
-
Publication number: 20070254315Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of ?-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.Type: ApplicationFiled: June 8, 2007Publication date: November 1, 2007Applicant: THE INSTITUTE FOR ETHNOMEDICINEInventors: Paul Cox, Sandra Banack, Susan Murch
-
Patent number: 7256002Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of ?-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.Type: GrantFiled: December 8, 2003Date of Patent: August 14, 2007Assignee: The Institute for EthnomedicineInventors: Paul A Cox, Sandra A Banack, Susan Murch